RAPT Therapeutics (RAPT) Competitors $0.85 -0.02 (-2.79%) As of 10:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. PGEN, MAZE, PRTC, ABVX, AUTL, ETON, RVNC, RAPP, AMLX, and ZVRAShould you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include Precigen (PGEN), Maze Therapeutics (MAZE), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), Autolus Therapeutics (AUTL), Eton Pharmaceuticals (ETON), Revance Therapeutics (RVNC), Rapport Therapeutics (RAPP), Amylyx Pharmaceuticals (AMLX), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. RAPT Therapeutics vs. Precigen Maze Therapeutics PureTech Health ABIVAX Société Anonyme Autolus Therapeutics Eton Pharmaceuticals Revance Therapeutics Rapport Therapeutics Amylyx Pharmaceuticals Zevra Therapeutics RAPT Therapeutics (NASDAQ:RAPT) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Do analysts prefer RAPT or PGEN? RAPT Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 370.59%. Precigen has a consensus price target of $7.00, indicating a potential upside of 353.07%. Given RAPT Therapeutics' higher possible upside, equities research analysts clearly believe RAPT Therapeutics is more favorable than Precigen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RAPT Therapeutics 1 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.11Precigen 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in RAPT or PGEN? Precigen received 346 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. Likewise, 67.44% of users gave Precigen an outperform vote while only 63.19% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformRAPT TherapeuticsOutperform Votes9163.19% Underperform Votes5336.81% PrecigenOutperform Votes43767.44% Underperform Votes21132.56% Which has more volatility & risk, RAPT or PGEN? RAPT Therapeutics has a beta of -0.29, indicating that its share price is 129% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Is RAPT or PGEN more profitable? RAPT Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. RAPT Therapeutics' return on equity of -89.10% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets RAPT TherapeuticsN/A -89.10% -76.13% Precigen -3,521.68%-123.06%-87.33% Do insiders and institutionals hold more shares of RAPT or PGEN? 99.1% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 6.6% of RAPT Therapeutics shares are held by company insiders. Comparatively, 44.9% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to RAPT or PGEN? In the previous week, RAPT Therapeutics had 2 more articles in the media than Precigen. MarketBeat recorded 2 mentions for RAPT Therapeutics and 0 mentions for Precigen. RAPT Therapeutics' average media sentiment score of 1.43 beat Precigen's score of 0.00 indicating that RAPT Therapeutics is being referred to more favorably in the media. Company Overall Sentiment RAPT Therapeutics Positive Precigen Neutral Which has preferable earnings & valuation, RAPT or PGEN? Precigen has higher revenue and earnings than RAPT Therapeutics. Precigen is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRAPT Therapeutics$1.53M73.34-$116.80M-$3.11-0.27Precigen$3.93M115.74-$95.90M-$0.48-3.22 SummaryPrecigen beats RAPT Therapeutics on 10 of the 18 factors compared between the two stocks. Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRAPT TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$112.07M$6.55B$5.37B$7.70BDividend YieldN/A3.20%5.44%4.32%P/E Ratio-0.316.9722.0918.22Price / Sales73.34266.04398.07105.44Price / CashN/A65.6738.2034.62Price / Book0.206.436.704.18Net Income-$116.80M$142.50M$3.20B$247.50M7 Day Performance7.53%7.39%5.27%5.92%1 Month Performance-45.51%-6.39%-4.75%-3.62%1 Year Performance-89.10%-0.84%17.44%4.75% RAPT Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRAPT Therapeutics3.6615 of 5 stars$0.85-2.8%$4.00+370.6%-88.9%$112.07M$1.53M-0.3180Positive NewsPGENPrecigen3.0602 of 5 stars$1.37-1.4%$7.00+410.9%+12.0%$402.84M$3.93M-2.49190Positive NewsGap UpMAZEMaze TherapeuticsN/A$9.13+8.6%$25.67+181.1%N/A$399.86M$167.50M0.00121News CoveragePRTCPureTech Health1.8872 of 5 stars$16.64-0.6%$45.00+170.5%-38.0%$399.56M$3.33M0.00100ABVXABIVAX Société Anonyme1.8435 of 5 stars$6.23-2.7%$38.00+510.0%-56.4%$395.10MN/A0.0061Gap UpAUTLAutolus Therapeutics2.4279 of 5 stars$1.44+0.7%$9.32+547.2%-66.7%$383.18M$10.12M-1.19330Analyst RevisionNews CoveragePositive NewsETONEton Pharmaceuticals2.1279 of 5 stars$14.26-0.6%$27.67+94.0%+391.9%$382.43M$39.01M-64.8220RVNCRevance Therapeutics2.0429 of 5 stars$3.65flat$8.39+129.7%N/A$381.02M$234.04M-1.89500RAPPRapport Therapeutics1.8379 of 5 stars$10.38+2.3%$32.67+214.7%N/A$378.83MN/A-0.75N/AAMLXAmylyx Pharmaceuticals2.9681 of 5 stars$4.23+6.3%$8.00+89.1%+178.7%$374.79M$87.37M-1.11200ZVRAZevra Therapeutics2.6254 of 5 stars$6.87-3.9%$22.29+224.4%+58.8%$371.78M$23.61M-3.4920Positive News Related Companies and Tools Related Companies Precigen Competitors Maze Therapeutics Competitors PureTech Health Competitors ABIVAX Société Anonyme Competitors Autolus Therapeutics Competitors Eton Pharmaceuticals Competitors Revance Therapeutics Competitors Rapport Therapeutics Competitors Amylyx Pharmaceuticals Competitors Zevra Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RAPT Stock Free RAPT Stock Alerts